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Abstract
Background: Analysis of large sets of biological sequence data from related strains or organisms is complicated by
superficial redundancy in the set, which may contain many members that are identical except at one or two
positions. Thus a new method, based on deriving physicochemical property (PCP)-consensus sequences, was tested
for its ability to generate reference sequences and distinguish functionally significant changes from background
variability.
Methods: The PCP consensus program was used to automatically derive consensus sequences starting from
sequence alignments of proteins from Flaviviruses (from the Flavitrack database) and human enteroviruses, using a
five dimensional set of Eigenvectors that summarize over 200 different scalar values for the PCPs of the amino
acids. A PCP-consensus protein of a Dengue virus envelope protein was produced recombinantly and tested for its
ability to bind antibodies to strains using ELISA.
Results: PCP-consensus sequences of the flavivirus family could be used to classify them into five discrete groups
and distinguish areas of the envelope proteins that correlate with host specificity and disease type. A multivalent
Dengue virus antigen was designed and shown to bind antibodies against all four DENV types. A consensus
enteroviral VPg protein had the same distinctive high pKa as wild type proteins and was recognized by two
different polymerases.
Conclusions: The process for deriving PCP-consensus sequences for any group of aligned similar sequences, has
been validated for sequences with up to 50% diversity. Ongoing projects have shown that the method identifies
residues that significantly alter PCPs at a given position, and might thus cause changes in function or
immunogenicity. Other potential applications include deriving target proteins for drug design and diagnostic kits.
Background
The most useful information one can glean from aligned
sequences of proteins is first, the absolutely conserved
residues, which are usually those that maintain the struc-
ture of the protein or are vital for function. The pattern,
or profile of conserved residues in an alignment of a
protein type can be used to identify proteins in the same
group, that may have a similar structure [1-4]. In addi-
tion, the variance within the sequences, which may occur
at specific positions due to random variation (i.e., in
RNA viruses, an error prone polymerase), can also indi-
cate a functional change. It is thus important to be able
to separate background variation, which, in our approach,
is assumed to cause little change in the physicochemical
properties (PCPs) at a position, from those that alter
these properties sufficiently to lead to a variance in pro-
tein function or immunogenicity [5-8].
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Very large alignments present intrinsic problems in
discriminating residue conservation or patterns of var-
iance, and require special software even to view them.
Another problem in dealing with biological datasets,
such as the many Flavivirus sequences we have collected
within the Flavitrack database [9,10], is that they often
have a pronounced bias due to unequal distribution,
which can arise from non-uniform sampling [11]. For
example, one may have many closely related sequences
from one epidemic, where serious infections occurred,
but few from the intervening years, when most infec-
tions had a less lethal phenotype. Conventional methods
for calculating consensus sequences assume an unbiased
data set, and typically calculate only the most common
amino acid in a column [12]. An example of such a con-
sensus (Figure 1A) shows that while it provides useful
information on the degree of conservation of the amino
acids in aligned sequences, it cannot suggest a rational
choice of amino acid at highly variant positions. Profil-
ing methods [13-15] based on amino acid scoring
matrices can also be used to obtain a consensus
sequence, but these are primarily designed to detect dis-
tantly related members of a set of proteins.
Here we show applications of a general method to cal-
culate physicochemical property (PCP)-consensus
sequences. The method is designed to filter noise due to
random amino-acid variations within strains or subtypes
from more significant variation. We first modeled PCP-
consensus sequences for several proteins, and showed
that they were stable after minimization with our FAN-
TOM program. We have also produced several PCP-con-
sensus proteins from synthetic gene sequences in E. coli
and tested their ability to be recognized enzymatically
and immunologically. As discussed below, PCP-consen-
sus sequences have many uses, in sequence classification,
epitope comparison, in defining multivalent sequences as
immunogens for vaccine use, and for defining targets for
multivalent drug design.
Methods
Deriving PCP consensus sequences
Our method assumes that one has a high quality align-
ment, of any number N of sequences with a maximum
length L. Choosing an appropriate sequence grouping is
a chicken/ egg problem, and will be discussed in more
detail below. Multiple sequence alignments were
Figure 1 Dealing with variable positions in aligned sequences. A consensus that chooses only the most frequently occurring amino acid at
a given column of an alignment (e.g., that from the Jalview applet of Clustal W) is best for indicating highly conserved residues, but does not
give any consensus value for variable positions (such as those circled). B) A PCP-consensus for the same sequences selects the amino acid that is
most similar in properties to all others in the set.
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generated with Clustalw 2.0.3[16], or MUSCLE [17,18],
for very large alignments, using default parameters. It is
best to check such large alignments for inappropriate
gapping. Although there are statistical methods to do
this [19], for the purposes of this early validation work,
we have chosen homologous proteins where a represen-
tative protein structure is known, and sequence group-
ings that have more than 50% identity. This allows us to
check that any gapping is consistent with secondary
structure elements, and conservation of disulfide bonds
and salt bridges.
Figure 2 compares the differences in the purpose and
method for obtaining a PCP consensus sequence with
those of profiling methods. To obtain PCP-consensus
sequences, at each position of the multiple alignment,
one amino acid is chosen that best approximates the
average value of the PCPs. The PCPs of the 20 amino
acids are defined by a set of numerical descriptors, 5
Eigenvectors obtained by multidimensional scaling of
over 200 unique property measurements [20]. Each
amino acid can be discriminated from all the others as
points in a five dimensional space, where the five
dimensions, the first 5 eigenvectors, roughly correspond
to hydrophobicity/hydrophilicity (E1); size (E2); alpha-
helix propensity (E3); the property E4 is related to the
partial specific volume, number of codons and relative
abundance of the amino acids; and E5 correlates weakly
with beta-strand propensity [20]. This 5-dimensional
approach to similarity allows one to calculate a true
consensus amino acid, i.e., the one closest in its PCPs to
all others in the column, even at very variable positions.
Given an amino acid alignment, the program selects an
amino acid that is closest in the property space to the
average values for all the other amino acids at each
position. First, the average value of each of the 5 PCP-
vectors p=E1,..,E5 is determined at each column, effec-
tively turning an alignment of N sequences of maximum













where N is the number of amino acids in the given
column of the alignment; and Vj
p , the value for the
relevant p eigenvector for the jth amino acid. Then the
consensus amino acid (Aa) is chosen from those occur-
ring naturally at that position with the least Euclidean
distance from the average:










The alignment independent scale factors bp were cal-
culated so that vector values with higher relative entro-
pies at a given column would be more significant, and
were calculated as described elsewhere [9].
For very variable positions or highly biased datasets,
the amino acids that naturally occur at each position
can be used one time, without regard to their rate of
Figure 2 Comparing the PCP-consensus method and its uses to profiling methods and their applications.
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occurrence in the column, to calculate the average
values of the 5 property vectors. In that case, equation 2
can still be used, and the chosen “consensus” amino
acid is simply that closest in its physical properties to all
the naturally occurring amino acids. Other possibilities
for dealing with bias in the data set, such as selective
sequence weighting can also be used [21] to determine
the property averaging method. This is an area for
further study, as a completely mathematical solution for
all situations is probably not possible.
It should be stressed that biological findings can be
incorporated at any point in this process, in distinguish-
ing sequences that have specific properties. Bioinforma-
ticians should be aware that sequences grouped
according to a biological assay may or may not correlate
with distinctive genotypes. For example, the four types
of Dengue viruses (DENV1-4), first characterized by
Sabin in the early fifties based on immunological reac-
tivity [22], segregate rather cleanly into four distinct
genotypes (see below). However, human enteroviruses
(HEV), designated Coxsackie virus A or B based on the
type of paralysis they caused in newborn mice, did not
separate neatly into two distinct sequence groups [23].
While we have relied on the strain designations in the
NCBI for Flaviviruses, other useful data that should be
part of the functional annotation (such as lethality) is
often not specified by those providing the sequences to
NCBI.
Models of PCP-consensus sequences were prepared
with our MPACK modeling suite [24-27] using the crys-
tal structure of the DENV-2 protein (1OAN.pdb) [28].
Results and discussion
PCP-consensus sequences using Flavitrack entries
There are many potential uses for PCP-consensus
sequences in virology, for example in classifying strains,
identifying functional alterations [29], and in designing
novel, multivalent antigens for vaccines and diagnostics.
Here we will show some applications based on data
stored in our Flavitrack database (http://carnot.utmb.
edu/flavitrack), which is a compendium of annotated
Flavivirus sequences [9,10]. Flaviviruses (FV), which
include yellow fever (YFV), DENV, and West Nile viruses
(WNV), are important human and animal pathogens
which typically require insect vectors to infect mamma-
lian hosts [30-35]. While mosquito control can be effec-
tive, antiviral agents and wide-spectrum vaccines are
being sought to protect those in endemic areas [36-43].
To design effective vaccines, the areas of the viral pro-
teins required for virus function or infectivity should be
targeted by antibodies. Flaviviruses are variable, with
many sequence variants found even in single virus iso-
lates from the same patient, so-called “quasispecies” [44].
However, when catalogued, the strains appear redundant
from a mathematical standpoint, with interstrain diver-
sity occurring at fewer than 1% of positions. While much
of this variation is neutral for phenotype, even a single
point mutation can greatly alter the immunogenicity of
the envelope protein or alter virus entry [38,40,45-47].
Recognizing such function-altering amino acid substitu-
tions is important for designing vaccines that will protect
against many Flaviviruses simultaneously, and entry
inhibitors.
Our first programs for analyzing the sequences in Flavi-
track attempted to highlight all variation in the aligned
sequences in a fashion suitable for conventional visual
scanning of the data. These first attempts illustrated the
need for unbiased data reduction: an alignment of 928
sequences (Flavitrack ca. 2009) covered dozens of pages
of paper. Even at the smallest possible type (a microtext
version of the database sequences provided to us by
Reiner Eschbach’s group at Xerox), no screen setting was
adequate to view more than a small part of the data. Also
for the purposes of determining variation, we needed a
rational mean sequence to compare sequences. Other
intrinsic problems in the data were the non-random
sequence distribution, with many more sequences avail-
able for certain mosquito-borne viruses (WNV and
DENV) than for any of the tick-borne or no-known-
vector (NKV) groups.
PCP-consensus reference strains
The traditional Flavivirus group reference strains are his-
torical isolates with defined immunological properties,
often predating the genome era, and not chosen to best
represent a consensus genotype. These strains may have
been passaged many times in the lab setting, a process
that could result in a sequence quite distant from the ori-
ginal or any subsequently isolated wild type strain. Now
that direct PCR sequencing from the original isolate is
possible, a more relevant methodology would be to use a
series of PCP-consensus reference strains, as long as
these were shown to correlate with serotype data or
other biological assays. We began by creating PCP-con-
sensus sequences for each group of Flaviviruses, where
the groups were defined according to the strain designa-
tions in the NCBI headers for the annotated sequences in
Flavitrack [48]. A series of 37 PCP-consensus strains for
the most common groups of Flaviviruses was derived
(Figure 3), which allowed comparison of the overall prop-
erties of the individual virus types and separated the
Flaviviruses, based on two different proteins, into five dis-
crete groupings. We suggest that these can be viewed as
reference strains for grouping (or profiling [49]) novel
Flavivirus isolates, obtained for example, from sentinel
screening of mosquitoes [50].
Proper grouping of virus isolates has meaning beyond
mere nomenclature: comparing these consensus
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sequences, we could discriminate residue changes that
fell outside the expected group variance. The compari-
son highlighted insertions and deletions that correlated
with whether a species was carried by mosquitoes or
ticks, and even with the type of disease (encephalitic vs.
haemolytic) resulting from human infection [48]. Addi-
tional uses of classification are to detect when a strain
that appeared to be adapted to growth only in mosqui-
toes or bats contained key substitutions that might indi-
cate human cross-over potential.
A multivalent PCP-consensus DENV antigen
Understanding the variation between viral types is parti-
cularly important for DENV, as it has been shown that
reinfection of a person carrying antibodies against one
DENV immunotype with a different type can result in
Dengue hemorrhagic fever (DHF), a severe disease that
requires proper medical support. In 2010, an epidemic in
Brazil caused over a million documented cases, with
about 600 deaths (many of which were young children).
Billions of people throughout the world are at risk for
DENV [43,51-55]. We approached this problem by gen-
erating a PCP-consensus of the representative envelope
proteins for the four different types of Dengue virus
(DENV1-4). This consensus was close to each type and
thus represented a good mean (Figure 4). This was espe-
cially clear for the outlier, DENV-4, which was lowest in
absolute identity to all the other three DENV types and is
the hardest to neutralize with antibodies generated by
infection with DENV-1,2 or 3. Figure 5 shows a portion
of the consensus envelope protein of Dengue, with resi-
dues of maximum variation highlighted. Optimal choice
of residues in variable areas of the viral strains can guide
the design of multivalent vaccines and inhibitors. Figure
6 shows how this sequence was further developed for
testing in animals. The recombinant protein, after opti-
mization to reflect the DENV4 outlier, bound antibodies
to all four DENV types [56] and preliminary work has
shown that inoculation of this protein generates multiva-
lent antibodies in rabbits and mice that neutralized all
four DENV strains (data not shown).
PCP-consensus VPg for designing multivalent inhibitors
of human enteroviruses
To further illustrate the potential uses of the method, we
designed and produced a PCP-consensus “viral peptide
linked to the genome” (VPg) for the human enteroviruses
(HEV), which include polioviruses (PV), Coxsackie
Figure 3 PCP-consensus sequences distinguish 5 groups of Flaviviruses. The PCP- consensus sequences of two viral proteins, the envelope
(E) and NS3 protease, of 37 different Flavivirus strains derived from 928 annotated entries in Flavitrack [48], separate into five distinct clusters,
based on their percent identity to one another.
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viruses A and B (CVA and CVB), and Echovirus. To initi-
ate RNA synthesis, HEV polymerases (3D-pol) uridylylate
a conserved tyrosine residue in the 22 amino acid long
VPg to form VPgpU. We have determined the NMR
structure of poliovirus type 1 (PV1)-VPg and PV1-
VPgpU and shown that uridylylation stabilized the
3D-structure of the peptide, which is probably necessary
for VPgpU to serve as a precursor for RNA synthesis
[57-59]. As this reaction is not found in normal cells, it is
a target for antiviral drug design [57]. To develop a
Figure 4 Identity matrix for four individual DENV consensus strains and a multivalent PCP consensus derived from them. The matrix
shows the inter-sequence Clustal W scores (top) or % Identity (bottom) for PCP-consensus sequences for the envelope protein of each of the
four DENV types, and a PCP consensus prepared from these four individual consensus sequences. The overall PCP-consensus is about equidistant
from the four consensus sequences, using either metric for similarity. Note the four distinct genotypes, that DENV 1 and 3 are closer to each
other than to DENV2, and that DENV4’s sequence is distant from the other 3 types.
Figure 5 Variable positions in a PCP-consensus DENV antigen. A model of a PCP-consensus EdomIII DENV antigen is shown in ribbon
format, with the sidechains where maximum variation occurs shown in stick format. Labels on the outermost residues are shown for orientation,
and to illustrate that the type specific epitope surfaces are not linearly encoded in the amino acid sequence.
Schein et al. BMC Bioinformatics 2012, 13(Suppl 13):S9
http://www.biomedcentral.com/1471-2105/13/S13/S9
Page 6 of 9
multivalent target VPg suitable for designing inhibitors
against all HEV, the sequences of 33 unique HEV-VPgs
were aligned and a PCP consensus protein, VPg-cons,
was prepared with our automatic program. Although
only about 50% of the amino acids were conserved com-
pletely the selected VPgs, the calculated pKa values of all
of them were exactly 10.46, suggesting the peptide must
be very basic in order to function (this is consistent with
our NMR structures, which shows the basic, essential
side chain of Arg17 very close to the phosphates of the
coupled UMP). The PCP-consensus VPg, which is not
identical to any naturally encoded sequence, had the
same calculated pKa of 10.46. This illustrates that the
consensus represents conserved physicochemical para-
meters of a sequence set. Both the PCP-consensus HEV-
VPg and HEV-VPgpU were prepared synthetically
[60,61]. The HEV-VPg can be uridylylated by both the
PV1- and CVA24-RNA-polymerases as well or better
than the wild type VPg encoded in their respective
genomes. Thus the PCP-consensus VPg represents the
conserved properties of HEV wild type VPgs, and func-
tions in a multivalent manner. Further study of the struc-
ture of the HEV-VPgpU should aid in deriving a general
mechanism for uridylylation. Inhibitors based on the con-
sensus HEV sequence should be multivalent, and prevent
replication of all HEVs.
Conclusions
Defining PCP-consensus sequences can aid in analysis
of large sequence datasets. The calculation method,
based on a previously validated 5D-vector scale for the
physicochemical properties of the amino acids, is
straightforward, once a suitable alignment of related
sequences is obtained. Having a rational consensus
allows one to distinguish residue variations that signifi-
cantly alter the properties at a given position. The
method is thus suitable for application to many types
of bioinformatics data.
Figure 6 Deriving a multivalent DENV antigen for testing in animals. Designing, producing and testing a multivalent DENV antigen for
vaccine use. The protein was able to bind antibodies generated against all four types of DENV, and induced antibodies in a rabbit that
recognized wild type proteins from all four types of DENV.
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The usefulness of the methodology in virology was
demonstrated in two practical applications. A multiva-
lent, PCP-consensus DENV vaccine candidate was
designed, produced, and shown to bind antibodies
against all four types of DENV. Also, a consensus HEV-
VPg has similar properties, particularly pKa, conserved
in wild type VPgs, and was uridylylated by two different
HEV polymerases. This validated method should find
application in many practical areas of virology and other
areas of biology.
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